Pioneering the Future of
Reproductive Medicine
with EV Technology
EXORPHIA is a biotechnology company leveraging its core
extracellular vesicle (EV) technologies to address infertility
and other medical challenges.
Our primary focus is next-generation embryo culture
technologies for in vitro fertilization.
Reproductive Medicine
with EV Technology
extracellular vesicle (EV) technologies to address infertility
and other medical challenges.
Our primary focus is next-generation embryo culture
technologies for in vitro fertilization.
News
- 2025.09.11NEWS RELEASEBreaking the Black Box of EV Therapeutics: EXORPHIA’s CMC Strategy to Be Showcased at an International Summit
-
2025.08.20NEWS RELEASEEXORPHIA and ROHTO Pharmaceutical Enter into Strategic Alliance to Advance Extracellular Vesicle Production Technology
Collaboration combines complementary strengths in regenerative medicine - 2024.05.23NEWS RELEASEEXORPHIA partners with Kyoritsu Holdings and Kyoritsu Seiyaku to jointly develop exosome-based therapeutics for pets